Optimization of the Arg8−Arg9 Cleavage Site in 68Ga-Labeled Neurotensin(6−13) Analogs for NTSR1-Targeted PET Imaging of Cancer

Abstract Neurotensin receptor 1 (NTSR1) is overexpressed in many cancers and represents a promising target for PET imaging. Neurotensin (NT)-derived radiopharmaceuticals targeting NTSR1 have been widely investigated; however, their clinical translation is limited in part by rapid proteolytic degradation, particularly at the Arg8−Arg9, Pro10−Tyr11, and Tyr11−Ile12 peptide bonds. In this study, we focused on optimizing the Arg8−Arg9 cleavage site through the incorporation of non-canonical amino acids to improve metabolic stability while maintaining high receptor affinity. A series of 16 DOTA-conjugated NT(6−13) analogs containing modifications at Arg8 and/or Arg9 were synthesized by solid-phase peptide synthesis. The natGa-labeled analogs were evaluated in PC-3 cells using a competition binding assay with [125I-Tyr3]Neurotensin, and compounds with Ki values < 5 nM were selected for 68Ga-radiolabeling, PET imaging, biodistribution, and in vivo stability studies. Ga-SK01033 (Phe(3-guanidine) at Arg8) and Ga-SK02040 (NMe-Orn(Me)3 at Arg8) demonstrated Ki values of 3.35 ± 0.32 and 4.34 ± 1.16 nM, respectively. Both peptides were labeled with 68Ga in 35.0−60.9% decay-corrected radiochemical yields, >108 GBq/μmol molar activity, and >97% radiochemical purity. Despite good binding affinity, [68Ga]Ga-SK01033 exhibited poor in vivo stability and negligible tumor uptake (<1 % ID/g at 1 h p.i., no intact tracer detected at 15 min p.i.). In contrast, [68Ga]Ga-SK02040 displayed improved metabolic stability, with 70.3 ± 5.11% intact tracer at 15 min p.i., resulting in tumor uptake of 11.1 ± 2.64 % ID/g at 1 h p.i. and 9.39 ± 2.64 % ID/g at 3 h p.i. Co-injection of excess natGa-SK02040 reduced tumor uptake by 91.2%, confirming NTSR1-mediated targeting. Overall, these findings demonstrate that while Phe(3-guanidine) substitution improves binding affinity without enhancing stability, incorporation of NMe-Orn(Me)3 at Arg8 simultaneously enhances affinity and metabolic stability, resulting in higher tumor uptake and tumor-to-non-target contrast than previously reported [68Ga]Ga-DOTA-NT-20.3. The present study establishes NMe-Orn(Me)3 as a favorable Arg8 modification that enables the development of NT(6−13)-based PET tracers with improved in vivo performance for targeting NTSR1.

Authors

Institutions

Publication Details

Journal
Molecular Pharmaceutics
Published
2026-11-12
DOI
https://doi.org/10.1021/acs.molpharmaceut.6c01104
Primary Topic
Radiopharmaceutical Chemistry and Applications
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Optimization of the Arg8−Arg9 Cleavage Site in 68Ga-Labeled Neurotensin(6−13) Analogs for NTSR1-Targeted PET Imaging of Cancer

Kuo‐Shyan Lin, François Bénard, Ka Yee Yee, Helen Merkens et al.
Molecular Pharmaceutics
Radiopharmaceutical Chemistry and Applications
article

Optimization of the Arg8−Arg9 Cleavage Site in 68Ga-Labeled Neurotensin(6−13) Analogs for NTSR1-Targeted PET Imaging of Cancer

Kuo‐Shyan Lin, François Bénard, Ka Yee Yee, Helen Merkens, Jutta Zeisler, Joseph Lau, Finnley Cookson, Sheetal Pathania, Pauline Ng, Stefan Mair (2430112), Simranjeet Kaur
article en

Abstract

Abstract Neurotensin receptor 1 (NTSR1) is overexpressed in many cancers and represents a promising target for PET imaging. Neurotensin (NT)-derived radiopharmaceuticals targeting NTSR1 have been widely investigated; however, their clinical translation is limited in part by rapid proteolytic degradation, particularly at the Arg8−Arg9, Pro10−Tyr11, and Tyr11−Ile12 peptide bonds. In this study, we focused on optimizing the Arg8−Arg9 cleavage site through the incorporation of non-canonical amino acids to improve metabolic stability while maintaining high receptor affinity. A series of 16 DOTA-conjugated NT(6−13) analogs containing modifications at Arg8 and/or Arg9 were synthesized by solid-phase peptide synthesis. The natGa-labeled analogs were evaluated in PC-3 cells using a competition binding assay with [125I-Tyr3]Neurotensin, and compounds with Ki values < 5 nM were selected for 68Ga-radiolabeling, PET imaging, biodistribution, and in vivo stability studies. Ga-SK01033 (Phe(3-guanidine) at Arg8) and Ga-SK02040 (NMe-Orn(Me)3 at Arg8) demonstrated Ki values of 3.35 ± 0.32 and 4.34 ± 1.16 nM, respectively. Both peptides were labeled with 68Ga in 35.0−60.9% decay-corrected radiochemical yields, >108 GBq/μmol molar activity, and >97% radiochemical purity. Despite good binding affinity, [68Ga]Ga-SK01033 exhibited poor in vivo stability and negligible tumor uptake (<1 % ID/g at 1 h p.i., no intact tracer detected at 15 min p.i.). In contrast, [68Ga]Ga-SK02040 displayed improved metabolic stability, with 70.3 ± 5.11% intact tracer at 15 min p.i., resulting in tumor uptake of 11.1 ± 2.64 % ID/g at 1 h p.i. and 9.39 ± 2.64 % ID/g at 3 h p.i. Co-injection of excess natGa-SK02040 reduced tumor uptake by 91.2%, confirming NTSR1-mediated targeting. Overall, these findings demonstrate that while Phe(3-guanidine) substitution improves binding affinity without enhancing stability, incorporation of NMe-Orn(Me)3 at Arg8 simultaneously enhances affinity and metabolic stability, resulting in higher tumor uptake and tumor-to-non-target contrast than previously reported [68Ga]Ga-DOTA-NT-20.3. The present study establishes NMe-Orn(Me)3 as a favorable Arg8 modification that enables the development of NT(6−13)-based PET tracers with improved in vivo performance for targeting NTSR1.

Molecular Pharmaceutics
University of British Columbia (CA)
University of British Columbia, BC Cancer Foundation
Good health and well-being
Radiopharmaceutical Chemistry and Applications
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon